New Protein Target Could Outperform Amlodipine and Losartan in Lowering Blood Pressure
Galectin-3 amplifies calcium channel activity in blood vessel walls — and blocking it slashes blood pressure more durably than standard drugs.
Summary
Hypertension remains a leading driver of cardiovascular aging. Researchers have now identified galectin-3 (Gal-3) as an unexpected amplifier of CaV1.2 calcium channels in vascular smooth muscle cells. When Gal-3 binds these channels, it increases their number on the cell surface and how often they open, causing blood vessels to contract more forcefully and raising blood pressure. In hypertensive rats and human arterial tissue, both Gal-3 and CaV1.2 were elevated. Deleting Gal-3 specifically in smooth muscle lowered blood pressure significantly in mice. The team designed a blocking peptide called iGal3BP that disrupts the Gal-3–CaV1.2 interaction; in hypertensive rats, repeated doses accumulated in arteries and produced longer-lasting blood pressure reduction than either amlodipine or losartan. Combining iGal3BP with a second peptide normalized systolic blood pressure within four hours and sustained the effect for 35 days.
Detailed Summary
Hypertension is one of the most prevalent age-related conditions, accelerating cardiovascular disease, stroke, kidney damage, and cognitive decline. Despite decades of drug development, many patients remain inadequately controlled on current therapies. Identifying new molecular targets within vascular smooth muscle is therefore a high priority for longevity medicine.
This study investigated galectin-3 (Gal-3), a carbohydrate-binding protein already implicated in cardiac fibrosis and inflammation, but never previously linked to calcium channel regulation in smooth muscle. The researchers used a broad toolkit — patch-clamp electrophysiology, pressure myography, immunohistochemistry, molecular binding assays, in silico modeling, conditional gene knockout mice, spontaneously hypertensive rats, and human arterial tissue — to map how Gal-3 interacts with CaV1.2, the L-type calcium channel that governs vascular tone.
The key finding is that Gal-3 binds the intracellular II-III loop of CaV1.2, increasing channel surface expression, current density, and open probability. This results in greater calcium influx and stronger smooth muscle contraction. Both Gal-3 and CaV1.2 were upregulated in hypertensive rat aortas and human pulmonary arteries, suggesting clinical relevance. Smooth muscle-specific Gal-3 knockout mice showed markedly reduced CaV1.2 protein and lower blood pressure.
The team then designed iGal3BP, a peptide that blocks the Gal-3–CaV1.2 interface. In hypertensive rats, iGal3BP outperformed amlodipine and losartan in durability, accumulating in mesenteric arteries with repeated dosing. Combining iGal3BP with a Gal-1 mimetic peptide that negatively modulates CaV1.2 restored normotensive systolic blood pressure within four hours and maintained that reduction for 35 days.
The main caveats are that this summary is based on the abstract only, the peptide has not been tested in humans, and long-term safety and delivery mechanisms require further study. Nevertheless, galectin-based CaV1.2 modulators represent a mechanistically novel antihypertensive strategy with potentially superior durability.
Key Findings
- Galectin-3 binds the CaV1.2 calcium channel's II-III loop, boosting surface expression and open probability in smooth muscle cells.
- Gal-3 and CaV1.2 are both upregulated in hypertensive rat aortas and human pulmonary arteries.
- Smooth muscle-specific Gal-3 gene deletion significantly lowered CaV1.2 protein levels and blood pressure in mice.
- Blocking peptide iGal3BP reduced blood pressure in hypertensive rats more durably than amlodipine or losartan.
- Combining iGal3BP with a Gal-1 mimetic peptide normalized systolic blood pressure within 4 hours and sustained effects for 35 days.
Methodology
The study used a multi-modal approach including patch-clamp electrophysiology, pressure myography, immunohistochemistry, in silico docking, and tail-cuff blood pressure measurements across HEK 293 cells, isolated smooth muscle cells, smooth muscle-specific Gal-3 knockout mice, spontaneously hypertensive rats, and human arterial tissue. In vivo peptide delivery experiments in hypertensive rats directly tested the antihypertensive efficacy of iGal3BP alone and in combination with a Gal-1 mimetic, with comparisons against amlodipine and losartan. No conflicts of interest were declared.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; detailed methodological and statistical information cannot be assessed. All in vivo pharmacology was conducted in rodent models, and human translation has not yet been demonstrated. Peptide delivery, bioavailability, dosing schedules, and long-term safety profiles in humans remain entirely unexplored.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: